SEATTLE, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that it will report its full year 2025 financial results and provide a business update on Monday, March 16, 2025 after the market closes. The press release will be available on the newsroom section of the Company's website at https://perspectivetherapeutics.co ...

Core Viewpoint - Perspective Therapeutics, Inc. has announced an underwritten offering of common stock and pre-funded warrants, aiming to raise approximately $175 million to support its clinical development and operational needs [1][3]. Group 1: Offering Details - The company is offering 39,576,088 shares of common stock at $3.79 per share and pre-funded warrants for 6,598,046 shares at $3.789 each, with gross proceeds expected to be around $175 million before expenses [1]. - The offering is set to close on or about February 3, 2026, pending customary closing conditions [1]. Group 2: Investor Participation - Notable investors in the financing include Commodore Capital, TCGX, Spruce Street Capital, Surveyor Capital, Affinity Asset Advisors, HBM Healthcare Investments, and Ally Bridge Group [2]. Group 3: Use of Proceeds - The net proceeds from the offering will be utilized for advancing clinical development, investing in manufacturing facilities, and general corporate purposes, with potential for acquiring complementary products or technologies [3]. Group 4: Company Overview - Perspective Therapeutics is focused on developing advanced radiopharmaceutical treatments for cancer, utilizing proprietary technology that targets cancer cells with alpha-emitting isotopes [7]. - The company is also working on complementary imaging diagnostics to enhance treatment personalization and efficacy [7]. - Current clinical programs include neuroendocrine tumors, melanoma, and solid tumors, which are in Phase 1/2a trials in the U.S. [8].

Core Viewpoint - Perspective Therapeutics, Inc. is advancing its radiopharmaceutical development for cancer treatments and will present at the upcoming J.P. Morgan Healthcare Conference [1][2]. Company Overview - Perspective Therapeutics, Inc. specializes in radiopharmaceuticals, focusing on innovative cancer treatments using proprietary technology that employs the alpha-emitting isotope Pb to target cancer cells [2]. - The company is developing complementary imaging diagnostics that utilize the same targeting moieties, enhancing personalized treatment and patient outcomes through a "theranostic" approach [2]. Clinical Programs - The company's clinical programs include neuroendocrine tumor (VMT-α-NET), melanoma (VMT01), and solid tumor (PSV359), which are currently in Phase 1/2a imaging and therapy trials in the U.S. [3]. - Perspective is expanding its regional network of drug product candidate finishing facilities, supported by its proprietary Pb generator, to provide patient-ready products for clinical trials and commercial operations [3].

Core Insights - Perspective Therapeutics, Inc. announced that updated data on its [Pb]VMT-α-NET program will be presented at the ASCO-GI Congress 2026, scheduled for January 8 to 10, 2026 [1][2] Group 1: Company Overview - Perspective Therapeutics is focused on developing advanced radiopharmaceutical treatments for various cancers, utilizing proprietary technology that employs the alpha-emitting isotope Pb to target cancer cells [4][5] - The company is conducting a multi-center, open-label, dose-escalation study of [Pb]VMT-α-NET in patients with unresectable or metastatic SSTR2-positive neuroendocrine tumors [3][4] Group 2: Clinical Data and Efficacy - As of the data cut-off date of September 12, 2025, safety findings from 55 patients indicated a favorable safety profile for [²¹²Pb]VMT-α-NET, with no dose-limiting toxicities or Grade 4 or 5 treatment-emergent adverse events reported [4][6] - Among 25 patients evaluated, 20 (80%) remained progression-free, and 8 patients achieved confirmed responses, all from Cohort 2, with a median follow-up of 41 weeks [6]

Core Insights - Perspective Therapeutics, Inc. is focused on developing advanced radiopharmaceutical treatments for various cancers using proprietary technology that employs the alpha-emitting isotope Pb to target cancer cells specifically [2][3] Group 1: Company Overview - Perspective Therapeutics is pioneering advanced treatments for cancers throughout the body with a focus on radiopharmaceuticals [2] - The company utilizes a "theranostic" approach, combining treatment and imaging diagnostics to personalize cancer therapy and optimize patient outcomes [2] - The company is currently conducting Phase 1/2a imaging and therapy trials for its neuroendocrine tumor (VMT-α-NET), melanoma (VMT01), and solid tumor (PSV359) programs in the U.S. [3] Group 2: Upcoming Events - Members of the senior leadership team will participate in the Piper Sandler & Co. 37th Annual Healthcare Conference on December 2, 2025, from 1:00 to 1:25 p.m. ET in New York, NY [1] - The company will also be present at the Evercore 8th Annual Healthcare Conference on December 3, 2025, from 3:00 to 3:20 p.m. ET in Miami, FL [1] Group 3: Operational Developments - Perspective Therapeutics is expanding its regional network of drug product candidate finishing facilities, supported by its proprietary Pb generator, to provide patient-ready products for clinical trials and commercial operations [3]

Core Insights - Perspective Therapeutics, Inc. is a radiopharmaceutical development company focused on advanced cancer treatments using proprietary technology that employs the alpha-emitting isotope Pb for targeted radiation delivery to cancer cells [2][3] Company Overview - The company is pioneering advanced treatments for various cancers and is developing complementary imaging diagnostics that utilize the same targeting moieties, allowing for personalized treatment and optimized patient outcomes [2] - The "theranostic" approach enables visualization of specific tumors followed by targeted treatment, potentially improving efficacy and minimizing toxicity [2] Clinical Development - The company's neuroendocrine tumor (VMT-α-NET), melanoma (VMT01), and solid tumor (PSV359) programs are currently in Phase 1/2a imaging and therapy trials in the U.S. [3] - Perspective Therapeutics is expanding its regional network of drug product candidate finishing facilities, supported by its proprietary Pb generator, to provide patient-ready product candidates for clinical trials and commercial operations [3] Upcoming Events - Members of the senior leadership team will participate in the Truist Securities BioPharma Symposium on November 6, 2025, in New York, NY, for one-on-one meetings with investors [1] - The company will also be featured in a Fireside Chat at the UBS Global Healthcare Conference on November 11, 2025, from 4:15 to 4:50 p.m. ET in Palm Beach, FL [2]

Core Insights - The FDA has set a Prescription Drug User Fee Act (PDUFA) date of March 29, 2026, for Lantheus Holdings' LNTH-2501, a diagnostic kit for neuroendocrine tumors [1][2] Company Overview - Lantheus Holdings, Inc. is a leading radiopharmaceutical-focused company dedicated to improving patient outcomes through innovative diagnostic solutions [5] - The company has been providing radiopharmaceutical solutions for nearly 70 years and operates globally with offices in multiple countries [5] Product Details - LNTH-2501 (Gallium-68 edotreotide) is designed for use with positron emission tomography (PET) imaging to localize somatostatin receptor-positive neuroendocrine tumors (SSTR+ NETs) in both adult and pediatric patients [1][4] - The product is submitted under the FDA's 505(b)(2) pathway, supported by extensive evidence from multiple published studies [2][4] - If approved, LNTH-2501 may complement Lantheus' therapeutic candidate PNT2003, enhancing the company's strategy for integrated diagnostic and therapeutic solutions [4] Market Context - Neuroendocrine tumors (NETs) are rare cancers, with over 170,000 individuals in the U.S. living with these conditions, and gastroenteropancreatic NETs (GEP-NETs) account for 55-70% of cases [3] - Due to their slow growth and non-specific symptoms, up to 50% of NETs are initially misdiagnosed, leading to delays in treatment [3]

Core Insights - Perspective Therapeutics, Inc. is set to report its third quarter 2025 financial results and provide a business update on November 10, 2025, after market close [1] Company Overview - Perspective Therapeutics, Inc. specializes in radiopharmaceutical development, focusing on advanced cancer treatments using proprietary technology that employs the alpha-emitting isotope Pb to target cancer cells [2] - The company is also developing complementary imaging diagnostics that utilize the same targeting moieties, allowing for personalized treatment and optimized patient outcomes through a "theranostic" approach [2] Clinical Programs - The company's neuroendocrine tumor (VMT-α-NET), melanoma (VMT01), and solid tumor (PSV359) programs are currently in Phase 1/2a imaging and therapy trials in the U.S. [3] - Perspective Therapeutics is expanding its regional network of drug product candidate finishing facilities, supported by its proprietary Pb generator, to provide patient-ready products for clinical trials and commercial operations [3]

Core Insights - Perspective Therapeutics, Inc. announced updated interim results from its Phase 1/2a clinical trial of [Pb]VMT-α-NET for treating unresectable or metastatic neuroendocrine tumors (NETs) at the ESMO Congress 2025 [1][2] Clinical Trial Results - The interim results were based on a data cut-off date of September 12, 2025, involving 55 patients across three dose cohorts who received at least one treatment of VMT-α-NET [2] - The objective response rate was reported at 44% (7 of 16 patients) in Cohort 2, with a median follow-up of 41 weeks, and 14 out of 16 patients remained free from progression [5][6] - Safety findings indicated no dose-limiting toxicities, no treatment-related discontinuations, and no serious renal complications among the patients [6] Expert Commentary - Richard Wahl, a professor at Washington University, highlighted the durable anti-tumor activity and excellent tolerability of [Pb]VMT-α-NET, emphasizing its potential as a treatment option for progressive NETs [4] - Markus Puhlmann, Chief Medical Officer, noted the compelling clinical profile of VMT-α-NET at the 5 mCi dose and the importance of the study for future registration [4] Future Developments - Initial efficacy data for an additional 23 patients in Cohort 2 and 8 patients in Cohort 3 are expected to be presented in 2026 [5][9] - The company is exploring whether a higher dose or refined patient selection criteria could enhance VMT-α-NET's clinical profile [7] Financial Position - As of September 30, 2025, the company's cash, cash equivalents, and short-term investments were approximately $174.1 million, expected to fund operations into late 2026 [8]

Core Insights - Perspective Therapeutics, Inc. has appointed Maya Martinez-Davis as an independent director to its Board of Directors, effective immediately [1][3] - Ms. Martinez-Davis brings extensive experience in the pharmaceutical industry, having held leadership roles at GSK, Merck KGaA, and Pfizer, particularly in oncology and specialty products [2][3] - The company is focused on pioneering advanced radiopharmaceutical treatments for cancer, utilizing proprietary technology that employs alpha-emitting isotopes for targeted therapy [4][5] Company Overview - Perspective Therapeutics specializes in radiopharmaceuticals aimed at treating various cancers, leveraging alpha-emitting isotopes to deliver radiation directly to cancer cells [4] - The company is developing complementary imaging diagnostics to personalize treatment and optimize patient outcomes through a "theranostic" approach [4] - Current clinical-stage programs include treatments for neuroendocrine tumors (VMT-α-NET), melanoma (VMT01), and solid tumors (PSV359), which are in Phase 1/2a trials in the U.S. [5] Leadership and Strategic Direction - Lori Woods, Chairperson of Perspective, expressed enthusiasm about Ms. Martinez-Davis joining the board, highlighting her complementary experience to existing directors and management [3] - Ms. Martinez-Davis aims to contribute insights to advance the company's clinical programs and enhance shareholder value [3] - CEO Thijs Spoor emphasized the potential of the company's innovative science to develop new medicines that could significantly improve patient lives [3]